FDA panel to review Grail’s Galleri test

The FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to convene on September 23, 2026 to evaluate Grail's (GRAL) Galleri multi-cancer blood test. The meeting will focus on whether the evidence submitted by the company supports authorization of the test and the scope of potential marketing claims.

Galleri is a blood-based test that Grail (GRAL) says can detect up to 50 types of cancer. It is being reviewed as a multi-cancer early detection tool intended for use in individuals without a cancer diagnosis, which places particular emphasis on analytical reliability and clinical performance in asymptomatic populations.

In briefing materials released ahead of the advisory meeting, FDA staff reported no outstanding major concerns about Galleri's analytical performance or primary safety analyses. These documents indicate that the agency's internal review has not identified significant unresolved issues related to how the test functions or to its safety profile.

However, the briefing documents ask external advisers to consider whether the available clinical data are sufficient to support marketing Galleri specifically as an "early detection" test. Panel members are expected to discuss how the evidence translates into claims that can be made to clinicians and patients, including how results should be interpreted in routine practice.

The advisory committee will review large clinical studies cited by Grail in support of Galleri. These include a study conducted with the U.K. National Health Service involving more than 140,000 participants, designed to assess the test's performance in a broad, real-world screening context.

A separate North American study of over 35,000 patients aged 50 and older will also be a central part of the evidence package. Together, these datasets provide information on how often the test detects signals that may indicate cancer and how it performs across a wide range of individuals who are at typical screening ages.

The advisory panel's recommendations will help shape how Galleri can be positioned in the market if cleared or approved. Discussions are likely to address how to convey the test's capabilities and limitations, including the distinction between detecting a cancer signal and confirming a diagnosis through follow-up procedures.

While the panel’s vote will be nonbinding, its assessment of the evidence base and of appropriate labeling will be an important factor in the FDA's subsequent decision-making. The outcome will guide how multi-cancer blood tests like Galleri may be integrated into future cancer screening strategies in clinical practice.